Overview

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Phase:
Phase 1
Details
Lead Sponsor:
St Vincent's Institute of Medical Research